Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(18 sites) United States
University of Alabama at Birmingham (UAB), Birmingham, Alabama Yale Cancer Center, New Haven, Connecticut Icahn School of Medicine at Mount Sinai (ISMMS), New York, New York The Ohio State University, Columbus, Ohio Magee-Woman's Hospital, Harrisburg, Pennsylvania SCRI Oncology Partners, Nashville, Tennessee Australia
St Vincent's Hospital Sydney, Darlinghurst, New South Wales Peter Maccallum Cancer Centre, Melbourne, Victoria Canada
British Columbia Cancer Agency - 600 10th Ave W, Vancouver, British Columbia Princess Margaret Cancer Centre, Toronto, Ontario Singapore
National University Hospital, Singapore National Cancer Centre, Singapore United Kingdom
Addenbrooke's Hospital, Cambridge Leicester Royal Infirmary, Leicester St Bartholomew's Hospital, London Sarah Cannon Research Institute, London Churchill Hospital, Oxford The Royal Marsden hospital, Sutton